🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

27 recruiting trials

for Recurrent Mantle Cell Lymphoma

Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma NCT06839053Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07578077Phase 1, Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Golcadomide Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) NCT07082686Phase 229 sites📍 Hefei📍 Beijing📍 Chengdu Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-248 BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites📍 Duarte📍 Stanford📍 Kansas City PeproMene Bio, Inc. · Tests: BAFFR-CAR T cells AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma NCT07788118Phase 1, Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: 7×19-THEMIS CAR-T cells Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy NCT07003295Phase 211 sites📍 Duarte📍 Atlanta📍 Atlanta National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT06675123Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, BTK Inhibitor Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites📍 Beijing📍 Beijing📍 Shanghai Medolution Ltd. · Tests: Keynatinib Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma NCT05432635Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modifie… Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy NCT07453095Phase 214 sites📍 Alessandria📍 Bologna📍 Brescia Fondazione Italiana Linfomi - ETS · Tests: Glofitamab Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma NCT07673367Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients NCT05098613Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T Cells Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy NCT07892027Phase 21 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel, Computed Tomography, Cyclophosphamide Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT05910801Phase 22 sites📍 Rochester📍 Houston Academic and Community Cancer Research United · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies NCT06980116Phase 117 sites📍 Tbilisi📍 Athens📍 Pátrai Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: EXS73565 Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07460362Phase 21 site📍 Beijing Peking University Third Hospital · Tests: Glofitamab, Lenalidomide B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies NCT06191887Phase 11 site📍 Jacksonville Mayo Clinic · Tests: Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy NCT07341191Phase 25 sites📍 Calgary📍 Edmonton📍 Vancouver Canadian Cancer Trials Group · Tests: Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy